Bumadizone
Star0
Identification
- Generic Name
- Bumadizone
- DrugBank Accession Number
- DB13286
- Background
-
Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis and gout1. Its use is restricted to these conditions, due to risks this drug poses1.
- Type
- Small Molecule
- Groups
- Approved
- Structure
-
- Weight
-
Average: 326.396
Monoisotopic: 326.163042576 - Chemical Formula
- C19H22N2O3
- Synonyms
-
- bumadizona
- Bumadizone
Pharmacology
- Indication
-
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
-
Not Available
- Mechanism of action
- Not Available
- Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
-
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Bumadizone may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Abciximab. Acebutolol Bumadizone may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Bumadizone. Acemetacin The risk or severity of adverse effects can be increased when Bumadizone is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Acenocoumarol. Acetaminophen The risk or severity of adverse effects can be increased when Acetaminophen is combined with Bumadizone. Acetohexamide The protein binding of Acetohexamide can be decreased when combined with Bumadizone. Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bumadizone. Aclidinium Bumadizone may decrease the excretion rate of Aclidinium which could result in a higher serum level. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- M01AB07 — Bumadizone
- Drug Categories
-
- Acetic Acid Derivatives and Related Substances
- Acids, Acyclic
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Antirheumatic Agents
- Dicarboxylic Acids
- Musculo-Skeletal System
- Nephrotoxic agents
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Sensory System Agents
- Chemical TaxonomyProvided byClassyfire
-
- Description
- This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Anilides
- Direct Parent
- Anilides
- Alternative Parents
- Phenylhydrazines/Medium-chain fatty acids/Branched fatty acids/Amino fatty acids/1,3-dicarbonyl compounds/Carboxylic acid hydrazides/Monocarboxylic acids and derivatives/Carboxylic acids/Organopnictogen compounds/Organonitrogen compounds show 2 more
- Substituents
- 1,3-dicarbonyl compound/Amino fatty acid/Anilide/Aromatic homomonocyclic compound/Branched fatty acid/Carbonyl group/Carboxylic acid/Carboxylic acid derivative/Carboxylic acid hydrazide/Fatty acid show 11 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- carbohydrazide, monocarboxylic acid (CHEBI:76119)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- ATD81G944M
- CAS number
- 3583-64-0
- InChI Key
- FLWFHHFTIRLFPV-UHFFFAOYSA-N
- InChI
-
InChI=1S/C19H22N2O3/c1-2-3-14-17(19(23)24)18(22)21(16-12-8-5-9-13-16)20-15-10-6-4-7-11-15/h4-13,17,20H,2-3,14H2,1H3,(H,23,24)
- IUPAC Name
-
2-(N,N'-diphenylhydrazinecarbonyl)hexanoic acid
- SMILES
-
CCCCC(C(O)=O)C(=O)N(NC1=CC=CC=C1)C1=CC=CC=C1
References
- 一般引用
-
- WHO - Consolidated list of products whoes consumption has been banned or withdrawn [Link]
- External Links
-
- ChemSpider
- 18080
- 19847
- ChEBI
- 76119
- ChEMBL
- CHEMBL2105456
- Wikipedia
- Bumadizone
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
-
Not Available
- 外包商
-
Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
-
Property Value Source Water Solubility 0.0541 mg/mL ALOGPS logP 2.95 ALOGPS logP 4.72 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 4.35 Chemaxon pKa (Strongest Basic) -7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 69.64 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 93.54 m3·mol-1 Chemaxon Polarizability 35.07 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like规则 No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
-
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at June 23, 2017 20:39 / Updated at February 21, 2021 18:54